

Pharmaceutical Benefits Scheme (PBS) Listings

1 August 2026

Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on **1 August 2026**.

This information relates to the administration of these listings by Services Australia. For further information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through the Services Australia website.

Hereditary tyrosinaemia type 1 (HT-1)

Nitisinone (2 mg; 5 mg; 10 mg; 20 mg capsule, 60; 4 mg/mL oral liquid, 90 mL) (Orfadin®) is now listed on the PBS for the treatment of HT-1. Authority applications for initial and grandfather treatments can be made using the Online PBS Authorities system or in writing. Authority applications for continuing treatment can be made using the Online PBS Authorities system or by telephone.

Severe established osteoporosis

Abaloparatide (2 mg/mL injection, 1.5 mL pen device) (Eladynos®) is now listed on the PBS for the treatment of severe established osteoporosis. Authority applications for initial and continuing treatments can be made using the Online PBS Authorities system or by telephone.

Fabry disease

Pegunigalsidase alfa (20 mg/10 mL injection, 10 mL vial) (Elfabrio®) is now listed on the PBS for the treatment of Fabry disease. Authority applications for initial and grandfather treatments can be made using the Online PBS Authorities system or in writing. Authority applications for continuing treatment can be made using the Online PBS Authorities system or by telephone.

Severe chronic plaque psoriasis

Tildrakizumab (100 mg/mL injection, 2 x 1 mL syringes) (Ilumya®) is now listed on the PBS for the treatment of severe chronic plaque psoriasis in patients 18 years or older. Authority applications for treatment can be made using the Online PBS Authorities system or in writing.

Type III Short bowel syndrome with intestinal failure

Teduglutide (5 mg injection [28 vials] (& inert substance diluent [28 x 0.5 mL syringes], 1 pack) (Revestive®) for the treatment of Type III Short bowel syndrome with intestinal failure has had an update to the restriction. Authority applications for initial and continuing treatments can be made using the Online PBS Authorities system or in writing.

Tumour-induced osteomalacia

Burosumab (10 mg/mL injection, 1 mL vial; 20 mg/mL injection, 1 mL vial; 30 mg/mL injection, 1 mL vial) (Crysvita®) is now listed on the PBS for the treatment of tumour-induced osteomalacia. Authority applications for initial, continuing and grandfather treatments can be made using the Online PBS Authorities system or by telephone.

Relapsed or refractory follicular lymphoma

Tafasitamab (200 mg injection, 1 vial) (MINJUVI®) is now listed on the PBS for the treatment of relapsed or refractory follicular lymphoma in combination with lenalidomide and rituximab for initial treatment and in combination with lenalidomide for continuing treatment. Authority applications for initial and continuing treatments can be made using the Online PBS Authorities system or by telephone.

Relapsed or refractory follicular lymphoma

Lenalidomide (5 mg; 10 mg; 15 mg; 20 mg capsule) (multiple brands) is now listed on the PBS for the treatment of relapsed or refractory follicular lymphoma in combination with tafasitamab and rituximab OR tafasitamab. Authority applications for treatment can be made using the Online PBS Authorities system or by telephone.

Malaria

Quinine (Quinine sulfate dihydrate 300 mg tablet, 50) (Quinate®) for the treatment of malaria has had a change in the authority level. Authority applications for treatment can be made using the Online PBS Authorities system or by telephone.

Advanced or metastatic medullary thyroid cancer

Selpercatinib (40 mg tablet, 56; 80 mg tablet, 56) (Retevmo®) is now listed on the PBS for the treatment of advanced or metastatic medullary thyroid cancer. Prescriptions for treatment are Authority Required (STREAMLINED).

Adult-type IDH-mutant astrocytoma or oligodendroglioma

Vorasidenib (10 mg tablet, 30; 40 mg tablet, 30) (Vorango®) is now listed on the PBS for the treatment of adult-type IDH-mutant astrocytoma or oligodendroglioma. Prescriptions for initial, continuing and grandfather treatments are Authority Required (STREAMLINED).

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Epcoritamab (4 mg/0.8 mL injection, 0.8 mL vial) (Epkinly®) for the treatment of DLBCL has had an update to the restriction. Authority applications for treatment can be made using the Online PBS Authorities system or by telephone.

Severe pain

Oxycodone hydrochloride (5 mg tablet, 20) (ENDONE®) (Mayne Pharma Oxycodone IR®) (Oxycodone Viatris®) (Oxyndone®); oxycodone hydrochloride 5 mg capsule, 20 (Oxycodone BNM®) (OxyNorm®) for the treatment of severe pain is now listed on the PBS as a Restricted benefit.

1 August 2026 delisted PBS listings**High-risk neuroblastoma**

Eflornithine (192 mg tablet, 100) (Ifinwil®) for the treatment of high-risk neuroblastoma no longer has a listing for grandfather arrangement.

Hereditary transthyretin amyloidosis

Patisiran (10 mg/5 mL injection, 5 mL vial) (Onpattro®) for the treatment of hereditary transthyretin amyloidosis has been de-listed with no supply only arrangements.

Asthma

Beclometasone dipropionate (100 microgram/actuation breath activated inhalation, 200 actuations) (Qvar 100 Autohaler®) for the treatment of asthma has been de-listed with a 6-month supply only period.

Diabetes type 1

Insulin lispro (100 units/mL injection, 1 x 10 mL vial) (Humalog®); insulin neutral human + insulin isophane human (30 units/mL + 70 units/mL injection, 10 mL vial) (Humulin 30/70®) for the treatment of type 1 diabetes has been de-listed with no supply only arrangements.

Fungal or yeast infection

Miconazole (miconazole 2% solution, 30 mL) (Daktarin Tincture®) for the treatment of fungal or yeast infection has been de-listed with a 3-month supply only period.

IMPORTANT INFORMATION**PBS Authorities – Changes from 1 August 2026****Moderate to severe Crohn disease – Paediatric (patients aged 6 – 17 years)**

Authority applications for **initial, change and recommencement treatment** for adalimumab and infliximab IV or SC can now be made using the Online PBS Authorities system or by telephone. Authority applications for **continuing treatment** for adalimumab and infliximab IV or SC are Authority Required (STREAMLINED).

Severe Crohn disease – ustekinumab IV load and SC maintenance authority applications

When applying for Initial 1 treatment with the ustekinumab IV formulation, and the SC formulation is being requested on the same day, the authority application for the SC formulation must be made under the Balance of Supply restriction.

**Integrated clinical and prescribing software**

Several clinical and prescribing software developers now have products available for use to request PBS authority approval directly from your clinical and prescribing software. This means you can request PBS authority approval as part of generating the authority prescription rather than calling, applying in writing or self-serving through the PBS Authorities tile in HPOS. For more information, speak with your software provider.

**Submitting Pharmaceutical Benefits Scheme (PBS) Written Applications through Health Professional Online Services (HPOS) form upload**

When submitting PBS authority forms through HPOS form upload, it is important to select the correct Form Category. For PBS patients, select PBS Authorities. For DVA patients, select RPBS Authorities. Remember that only yourself or your delegate/s are authorised to upload PBS and RPBS Authority applications.

Make sure you've:

- linked your prescriber number to your Provider Digital Access (PRODA) account for HPOS; and
- Set up your delegations in HPOS.

Visit servicesaustralia.gov.au/HPOS for more information on how to Link your Health Identifiers to HPOS and Manage delegations.



PBS Authorities items criteria

Under the PBS, medicines are made available based on recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC). Patients must meet the set criteria to be eligible for PBS subsidised medicines. Services Australia are unable to provide approval for an Authority Required medication where a patient does not meet the criteria established by PBAC.

If you have concerns or questions about the eligibility criteria set by the PBAC, you can contact the Department of Health, Disability and Ageing by email at pbs@health.gov.au.

REMINDERS



PBS Authorities – written authority application forms

To align with PBS listing changes, forms are updated on the first of the month. Using the most recent form will help avoid delays in obtaining authority approval. Search the Services Australia website to access the most recent forms.



Correct PBS item code

When requesting PBS authorities via the Online PBS Authorities system, ensure you have selected the correct medicine to match what is on the prescription. This will avoid delays with providing patients with the medication they require.



Ensuring you are providing accurate data

It's important to ensure you are providing accurate and up to date information when completing an authority application. Failure to do so may result in your authority request being rejected.



For more information about the Online PBS Authorities system visit www.servicesaustralia.gov.au/hppbsauthorities

Services Australia has a broad range of educational resources on the Health Professional Education Resources website. This includes simulations, podcast and an infographic on the Online PBS Authorities system. Visit <https://hpe.servicesaustralia.gov.au/pharmaceutical-benefits-scheme.html>

Visit servicesaustralia.gov.au/hpwrittenauthoritydrugs on the Services Australia website to find the most up to date authority application form for each drug, program or condition.